Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Yamin Shu,1– 4,* Qilin Zhang,5,* Xucheng He,6 Li Chen1– 3 1Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, People’s Rep...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shu Y, Zhang Q, He X, Chen L
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Dove Medical Press 2021-11-01
coleção:	Cancer Management and Research
Assuntos:	cost-effectiveness gefitinib nsclc egfr markov model
Acesso em linha:	https://www.dovepress.com/cost-effectiveness-analysis-of-gefitinib-plus-chemotherapy-versus-gefi-peer-reviewed-fulltext-article-CMAR
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!